Clinical Trial

Neoadjuvant Treatment of Ovarian Cancer With Fuzuloparib in Combination With Apatinib

Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
In this study, investigators propose to use fuzuloparib and apatinib as neoadjuvant therapy for Homologous recombination deficiency （HRD）positive advanced ovarian cancer patients, aiming to explore the efficacy and safety of this 'de-chemotherapy' regimen as neoadjuvant therapy for advanced ovarian cancer, and to conduct genetically related subgroup analyses, to guide the precision therapy and provide a new therapeutic option for HRD-positive patients with advanced ovarian cancer. To provide a new treatment option In order to increase the R0 resection rate of surgery and reduce chemotherapy resistance, thus improving the prognosis and prolonging the survival of patients.
Protocol Amendment History 1 amendment
This ClinicalTrials.gov record has been amended once since 2025-06-13.
Status change: Not Yet Recruiting → Recruiting 2026-02-25
Trial Details
NCT Number NCT07033819
Lead Sponsor Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Conditions Ovarian Cancer
Enrollment 48 participants
Start Date 2025-06-25
Primary Completion 2027-06-20 (estimated)
Study Completion 2028-06-01 (estimated)
Updated on ClinicalTrials.gov 2026-02-27